# Singleplex Immunoassay Market > Singleplex Immunoassay Market Research Report Information By Products and Services (Consumables, Others), by Type (Protein-Based Assays, Nucleic Acid Based Assays, Others), Technology (Flow Cytometry, Others), Application, End-User - Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.18% - **2024:** $ 197 Million - **2025:** $ 203.26 Million - **2035:** $ 277.98 Million - **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), PerkinElmer (US), Quidel Corporation (US) **Report ID:** MRFR/LS/4737-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/singleplex-immunoassay-market-6196 --- ## Market Summary ## **Global Singleplex Immunoassay Market Overview** Singleplex Immunoassay Market Size was valued at USD 0.186 Billion in 2023. The Global Singleplex Immunoassay industry is projected to grow from USD 0.197 Billion in 2024 to USD 0.207 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.34% during the forecast period (2024 - 2032). Singleplex immunoassays such as Enzyme-Linked Immunosorbent Assays (ELISA) or western blotting are used sequentially to analyze multiple intracellular and extracellular proteins. Moreover, singleplex immunoassay provides a fast and high-through output solution for gene expression quantification. For instance, , application, and end-user. ## **Global Singleplex Immunoassay Market Segmentation** On the basis of the product and services, the market is classified as consumables, instruments, and others. The global singleplex immunoassay market on the basis of the type is segmented as protein-based assays, nucleic acid-based assays, cell-based assays, and others. On the basis of technology, the market is segmented into flow cytometry, fluorescence detection, and others. The singleplex immunoassay global market, by application, is segmented into research and development, clinical diagnostics, and others. The research and development are further segmented into drug discovery & development and biomarker discovery and validation. The clinical diagnostics are further segmented into infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, and metabolism & endocrinology disorders. On the basis of the end-user, the market is segmented as pharmaceutical & biotechnology companies, hospitals & research institutes, reference laboratories and others. Geographically, the market has been segmented into America, Europe, Asia-Pacific, and the Middle East & Africa. The Americas singleplex [immunoassay market](../../../reports/immunoassay-market-5841) is further segmented into North America, and South America. North America is further classified as the US and Canada. The Europe market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UKUK, Italy, Spain, and the Rest of Western Europe. The Asia-Pacific market is segmented into Japan, China, India, Republic of Korea, Australia, and Rest of Asia-Pacific. The Middle East & Africa market is segmented into the Middle East, and Africa. ## **Global Singleplex Immunoassay Market Regional Analysis** The global singleplex immunoassay market consists of four regions: Americas, Europe, Asia-Pacific and the Middle East & Africa. The Americas is expected to dominate the singleplex immunoassay market owing to the presence of major market players, high adoption rate, and increasing prevalence of infectious diseases. According to the statistics suggested by the Centers for Disease Control (CDC) and Prevention, in 2014,  around 9,421 cases of tuberculosis, 51,455 cases of salmonella, 33,461 cases of Lyme disease, and 433 cases of [meningococcal](../../../reports/meningococcal-vaccines-market-8622) disease were registered in the United States. Europe is anticipated to hold the second position in the global singleplex immunoassay market. It is expected that the rising automation in an immunoassay, increasing prevalence of chronic diseases, funding provided by the government, and private organizations towards research & development are anticipated to drive the European market. The Asia-Pacific singleplex immunoassay market consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is the fastest growing in singleplex immunoassay market. Major factors such as growing patient pool, high incidence of chronic diseases, developing healthcare infrastructure and increasing research & development activities in the biotechnology sector, increasing healthcare expenditure influences the market in this region. Additionally, according to the data suggested by the Australian Institute of Health and Welfare during the year 2015-16, the total health expenditure was USD 170.4 billion, i.e., 3.6 % higher than the expenditure of 2014-2015. The Middle East and Africa hold the least share in the global singleplex immunoassay market due to the presence of stringent government policies and poor economies. However, growing awareness among the population and high investments by private market players in this region can boost the market growth. ## **Research Methodology** Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, Treatment assessment, competitive landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments & categories geographically presented are studied and are estimated based on primary & secondary research. ### **Primary Research** The extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years. ### **Secondary Research** Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the global singleplex immunoassay market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, & developments related to the market and Treatment Perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases and many others. ### **Global Singleplex Immunoassay Market, by Product and Service** ### **Global Singleplex Immunoassay Market, by Type** ### **Global Singleplex Immunoassay Market, by Technology** ### **Global Singleplex Immunoassay Market, by Application** ### **Global Singleplex Immunoassay Market, by End-user** ### **Global Singleplex Immunoassay Market, by Region** **Intended Audience** ## Market Drivers ### Market Growth Projections The Global Singleplex Immunoassay Market Industry is projected to experience substantial growth over the coming years. With a market value of 0.2 USD Billion in 2024, it is anticipated to reach 0.28 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate (CAGR) of 3.18% from 2025 to 2035. Factors contributing to this growth include rising demand for diagnostic testing, technological advancements, and increased investment in research and development. The market's expansion is likely to be driven by the continuous evolution of healthcare needs and the increasing focus on personalized medicine. ### Rising Demand for Diagnostic Testing The Global Singleplex Immunoassay Market Industry experiences a notable surge in demand for diagnostic testing across various healthcare settings. This trend is driven by the increasing prevalence of chronic diseases and the need for early detection. For instance, the market is projected to reach 0.2 USD Billion in 2024, reflecting a growing emphasis on personalized medicine and targeted therapies. As healthcare providers seek efficient and accurate testing methods, singleplex immunoassays offer a streamlined approach to diagnostics, thereby enhancing patient outcomes. This rising demand is likely to propel the market further, as stakeholders invest in innovative technologies and solutions. ### Growing Focus on Point-of-Care Testing The growing focus on point-of-care testing significantly influences the Global Singleplex Immunoassay Market Industry. As healthcare systems strive to improve patient access to diagnostics, singleplex immunoassays offer rapid results and ease of use in diverse settings. This shift towards decentralized testing is particularly relevant in rural and underserved areas, where traditional laboratory access may be limited. The convenience and efficiency of point-of-care testing are likely to drive market growth, as healthcare providers increasingly adopt these assays to enhance patient care. This trend aligns with the broader movement towards patient-centered healthcare solutions. ### Technological Advancements in Assay Development Technological advancements play a pivotal role in shaping the Global Singleplex Immunoassay Market Industry. Innovations in assay development, such as enhanced sensitivity and specificity, are driving the adoption of singleplex immunoassays in clinical laboratories. These advancements facilitate the detection of low-abundance biomarkers, which is crucial for disease diagnosis and monitoring. As a result, the market is expected to grow, reaching 0.28 USD Billion by 2035. Furthermore, the integration of automation and digital platforms in assay processes enhances efficiency and reduces turnaround times, making singleplex immunoassays more appealing to healthcare providers. ### Increased Investment in Research and Development Investment in research and development is a significant driver of the Global Singleplex Immunoassay Market Industry. As pharmaceutical and biotechnology companies focus on developing novel therapeutics, the demand for reliable diagnostic tools becomes paramount. This trend is evidenced by the projected compound annual growth rate (CAGR) of 3.18% from 2025 to 2035. Increased funding for research initiatives fosters innovation in assay technologies, enabling the development of more precise and user-friendly singleplex immunoassays. Consequently, this investment not only enhances the capabilities of existing assays but also paves the way for new applications in various fields, including oncology and infectious diseases. ### Regulatory Support for Innovative Diagnostic Solutions Regulatory support for innovative diagnostic solutions is a crucial driver of the Global Singleplex Immunoassay Market Industry. Governments and regulatory bodies are increasingly recognizing the importance of rapid and accurate diagnostics in improving public health outcomes. Streamlined approval processes for novel assays encourage manufacturers to invest in the development of singleplex immunoassays. This supportive regulatory environment fosters innovation and competition within the market, ultimately benefiting healthcare providers and patients alike. As a result, the market is poised for growth, with an increasing number of innovative products entering the landscape. ## Future Outlook The Singleplex Immunoassay Market is projected to grow at a 3.18% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for diagnostics, and rising healthcare expenditures. **New opportunities:** - Development of portable immunoassay devices for point-of-care testing. - Expansion into emerging markets with tailored diagnostic solutions. - Partnerships with biotech firms for innovative assay development. By 2035, the Singleplex Immunoassay Market is expected to achieve robust growth and enhanced market presence. ## Segment Insights ### By Application: Clinical Diagnostics (Largest) vs. Research and Development (Fastest-Growing) In the Singleplex Immunoassay Market, the application segment showcases a diverse distribution of market share among Clinical Diagnostics, Research and Development, Drug Discovery, and Environmental Testing. Clinical Diagnostics holds the largest share due to its critical role in patient diagnosis and monitoring, driving demand in healthcare settings. In contrast, Research and Development is experiencing rapid growth as laboratories expand their focus on innovative immunoassay techniques, reflecting a shift towards personalized medicine and advanced research capabilities. The growth trends in this segment are significantly influenced by advances in technology, increasing prevalence of diseases, and the necessity for early diagnostic solutions. The push towards automation and improved sensitivity in immunoassays further propels market dynamics. Moreover, the rise in funding for research projects related to drug discovery and environmental analysis facilitates the expanding use of Singleplex Immunoassays, positioning this sector for future growth potential. Clinical Diagnostics (Dominant) vs. Drug Discovery (Emerging) Clinical Diagnostics remains the dominant application within the Singleplex Immunoassay Market, leveraging its established position in detecting various health conditions with accuracy and efficiency. This sector is characterized by strict regulatory standards and a strong emphasis on quality assurance, meaning that the immunoassays developed within this space are essential for reliable healthcare delivery. In contrast, Drug Discovery is an emerging segment, increasingly recognized for its potential to enhance the drug development process by enabling faster identification of biomarkers and therapeutic targets. As pharmaceutical companies seek to streamline their development pipelines, the integration of Singleplex Immunoassays is becoming crucial, fostering innovation in drug development practices. ### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing) Within the Singleplex Immunoassay Market, hospitals account for the largest share, driven by their high patient volume and the need for rapid diagnostic services. Diagnostic laboratories are witnessing a fast-paced growth due to increasing demand for precise diagnostics and their ability to manage a wide array of tests efficiently. Hospitals are improving their testing capabilities, while diagnostic labs are expanding their market reach offering specialized assays. Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging) Hospitals play a dominant role in the Singleplex Immunoassay Market primarily because they require immediately available diagnostic results for patient care. They integrate various immunoassay technologies into their clinical workflows, ensuring timely treatment decisions. On the other hand, diagnostic laboratories represent an emerging segment that is rapidly evolving. They are expanding their services through innovative testing methods and automation, catering to the increasing demand from healthcare providers for specialized testing. This growth trajectory positions diagnostic laboratories as a critical component in enhancing patient care through advanced diagnostic solutions. ### By Technology: Enzyme-Linked Immunosorbent Assay (Largest) vs. Lateral Flow Assay (Fastest-Growing) The Singleplex Immunoassay Market is primarily dominated by the Enzyme-Linked Immunosorbent Assay (ELISA), which holds a significant share due to its extensive application in diagnostics and research. Following ELISA, the [Lateral Flow Assay](https://www.marketresearchfuture.com/reports/lateral-flow-assay-market-41765) is gaining traction, particularly in point-of-care testing, which has propelled its market presence. Other technologies such as Fluorescent and Chemiluminescent Immunoassays contribute to the overall diversity of the market but are currently overshadowed by these two leading methodologies. Growth trends in this segment indicate a continuous upward trajectory for lateral flow assays, driven by the demand for rapid and reliable testing solutions. Technological advancements and increasing investment in healthcare infrastructure further serve as catalysts for the growth of these immunoassays. Additionally, the rising prevalence of infectious diseases and chronic conditions emphasizes the need for innovative diagnostic tools, providing a robust environment for both established and emerging technologies to thrive. Technology: ELISA (Dominant) vs. Lateral Flow Assay (Emerging) The Enzyme-Linked Immunosorbent Assay (ELISA) is recognized as the dominant player in the Singleplex Immunoassay Market, characterized by its versatility, high sensitivity, and wide range of applications, including disease diagnosis and research. It employs enzyme-labeled antibodies to detect specific antigens, allowing for quantitative and qualitative analysis. On the other hand, the Lateral Flow Assay is emerging due to its ease of use, speed, and adaptability to a variety of conditions. Its ability to deliver rapid results without the need for specialized equipment makes it increasingly popular, especially in remote or resource-limited settings. This emerging segment, with its unique advantages, is poised to capture a larger share of the market as healthcare systems evolve. ### By Product Type: Kits (Largest) vs. Reagents (Fastest-Growing) In the Singleplex Immunoassay Market, the market share distribution reveals that Kits represent the largest segment, primarily due to their ease of use and comprehensive solutions provided for various testing needs. Reagents, although smaller in market share, are witnessing significant uptake fueled by increased demand from research and diagnostics laboratories seeking deeper insights and precision in their analyses. Instruments and Software segments play supportive roles, focusing on enhancing the performance and reliability of singleplex assays. Kits (Dominant) vs. Reagents (Emerging) Kits are considered the dominant product type in the Singleplex Immunoassay Market, offering an all-in-one solution that simplifies testing processes and ensures a high level of accuracy. They are preferred by laboratories due to their convenience and compatibility with various assays. On the other hand, Reagents are emerging as a critical component, driven by the need for high-quality materials that can be customized for specific assays. This shift is partly due to advancements in biotechnology that facilitate the development of more specialized products, ensuring better performance in singleplex immunoassays. ### By Target Analyte: Proteins (Largest) vs. Antibodies (Fastest-Growing) In the Singleplex Immunoassay Market, the segment of proteins holds the largest market share, reflecting its significance in various applications such as diagnostics and therapeutics. Hormones and pathogens also contribute to the market, though to a lesser extent, demonstrating the diverse range of target analytes used in immunoassays. Antibodies, while smaller in share, are gaining momentum and are critical for advanced diagnostic methodologies. Proteins: Dominant vs. Antibodies: Emerging Proteins, as a dominant target analyte in the Singleplex Immunoassay Market, are extensively utilized for their critical role in disease diagnosis and monitoring. Their well-established applications make them a staple in laboratories. On the other hand, antibodies represent an emerging segment, rapidly gaining traction due to advancements in immunoassay technologies. The prevalence of antibody-based tests in research and clinical diagnostics exemplifies their growth, driven by increasing R&D and the demand for specific targeting in disease detection. ## Regional Market Share Analysis ### North America : Market Leader in Innovation North America continues to lead the Singleplex Immunoassay Market, holding a significant market share of 98.5 in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of chronic diseases, and a strong focus on research and development. Regulatory support from agencies like the FDA further catalyzes innovation, ensuring rapid market responsiveness to emerging healthcare needs. The competitive landscape is robust, with key players such as Abbott Laboratories, Thermo Fisher Scientific, and Roche Diagnostics dominating the market. The U.S. remains the largest contributor, supported by a high demand for diagnostic solutions and continuous technological advancements. The presence of established companies fosters a dynamic environment, encouraging new entrants and innovations in the field. ### Europe : Emerging Market with Growth Potential Europe's Singleplex Immunoassay Market is poised for growth, with a market size of 50.0 in 2024. The region benefits from increasing investments in healthcare and biotechnology, alongside a rising demand for personalized medicine. Regulatory frameworks, such as the EU In Vitro Diagnostic Regulation, are enhancing product quality and safety, driving market expansion. Leading countries like Germany, France, and the UK are at the forefront, with a competitive landscape featuring major players like Siemens Healthineers and Bio-Rad Laboratories. The European market is characterized by a mix of established companies and innovative startups, fostering a collaborative environment for advancements in diagnostic technologies. The region's commitment to improving healthcare outcomes is evident in its support for research and development initiatives. ### Asia-Pacific : Rapidly Growing Healthcare Sector The Asia-Pacific region is witnessing significant growth in the Singleplex Immunoassay Market, with a market size of 35.0 in 2024. Factors such as increasing healthcare expenditure, rising awareness of early disease detection, and a growing population are driving demand. Additionally, government initiatives to improve healthcare infrastructure are acting as catalysts for market growth. Countries like China, India, and Japan are leading the charge, with a competitive landscape that includes both local and international players. Companies such as PerkinElmer and Quidel Corporation are expanding their presence, contributing to the region's dynamic market. The focus on technological advancements and collaborations with research institutions is expected to further enhance the market's growth trajectory. ### Middle East and Africa : Emerging Market with Challenges The Middle East and Africa (MEA) region is gradually developing its Singleplex Immunoassay Market, currently valued at 13.5 in 2024. The growth is driven by increasing healthcare investments, rising disease prevalence, and a focus on improving diagnostic capabilities. However, challenges such as regulatory hurdles and varying healthcare standards across countries may impede rapid growth. Countries like South Africa and the UAE are leading the market, with a mix of local and international players striving to establish a foothold. The presence of companies like Ortho [Clinical Diagnostics](https://www.marketresearchfuture.com/reports/clinical-diagnostic-market-41770) is notable, as they work to enhance diagnostic solutions in the region. Collaborative efforts between governments and private sectors are essential to overcome challenges and unlock the market's full potential. ## Competitive Benchmarking The Singleplex Immunoassay Market is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, leveraging their extensive research capabilities and technological advancements to enhance product offerings. Abbott Laboratories (US) focuses on expanding its diagnostic portfolio through strategic acquisitions, while Roche Diagnostics (CH) emphasizes innovation in assay development, particularly in personalized medicine. Thermo Fisher Scientific (US) appears to be concentrating on digital transformation initiatives, integrating advanced data analytics into their immunoassay platforms, which collectively enhances their competitive positioning in the market.The market structure is moderately fragmented, with a mix of established players and emerging companies vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of global economic fluctuations. The collective influence of these major players fosters a dynamic environment where innovation and operational efficiency are paramount. In November Roche Diagnostics (CH) announced the launch of a new singleplex immunoassay platform designed to streamline laboratory workflows and improve diagnostic accuracy. This strategic move is significant as it not only enhances Roche's product portfolio but also positions the company to better meet the growing demand for rapid and reliable diagnostic solutions in clinical settings. The introduction of this platform is likely to strengthen Roche's competitive edge in the market. In October Abbott Laboratories (US) expanded its collaboration with a leading biotechnology firm to develop next-generation immunoassays that utilize artificial intelligence for enhanced predictive analytics. This partnership is indicative of Abbott's commitment to integrating cutting-edge technology into its product development, potentially revolutionizing the way immunoassays are utilized in clinical diagnostics. Such advancements may lead to improved patient outcomes and greater operational efficiencies. In September Thermo Fisher Scientific (US) unveiled a new initiative aimed at enhancing sustainability in its manufacturing processes for immunoassays. This initiative includes the adoption of eco-friendly materials and energy-efficient technologies, reflecting a growing trend towards sustainability in the healthcare sector. By prioritizing environmental responsibility, Thermo Fisher not only addresses regulatory pressures but also appeals to a more environmentally conscious consumer base. As of December the competitive trends in the Singleplex Immunoassay Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing product offerings. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to evolving market demands. ## Report Scope | MARKET SIZE 2024 | 197.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 203.26(USD Million) | | MARKET SIZE 2035 | 277.98(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.18% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), PerkinElmer (US), Quidel Corporation (US) | | Segments Covered | Application, End Use, Technology, Product Type, Target Analyte | | Key Market Opportunities | Advancements in biomarker discovery enhance diagnostic capabilities within the Singleplex Immunoassay Market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the Singleplex Immunoassay Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation for the Singleplex Immunoassay Market in 2035?** A: The projected market valuation for the Singleplex Immunoassay Market in 2035 is 277.98 USD Million. **Q: What was the market valuation for the Singleplex Immunoassay Market in 2024?** A: The market valuation for the Singleplex Immunoassay Market in 2024 was 197.0 USD Million. **Q: What is the expected CAGR for the Singleplex Immunoassay Market from 2025 to 2035?** A: The expected CAGR for the Singleplex Immunoassay Market during the forecast period 2025 - 2035 is 3.18%. **Q: Which companies are considered key players in the Singleplex Immunoassay Market?** A: Key players in the Singleplex Immunoassay Market include Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific. **Q: What are the primary applications of Singleplex Immunoassays?** A: The primary applications of Singleplex Immunoassays include Clinical Diagnostics, Research and Development, Drug Discovery, and Environmental Testing. **Q: How do hospitals contribute to the Singleplex Immunoassay Market?** A: Hospitals contributed between 50.0 and 70.0 USD Million to the Singleplex Immunoassay Market in 2024. **Q: What product types are included in the Singleplex Immunoassay Market?** A: Product types in the Singleplex Immunoassay Market include Kits, Reagents, Instruments, and Software. **Q: What technologies are utilized in Singleplex Immunoassays?** A: Technologies utilized in Singleplex Immunoassays encompass Enzyme-Linked Immunosorbent Assay, Lateral Flow Assay, and Chemiluminescent Immunoassay. **Q: What target analytes are commonly measured using Singleplex Immunoassays?** A: Common target analytes measured using Singleplex Immunoassays include Proteins, Hormones, Antibodies, and Pathogens. **Q: What is the role of pharmaceutical companies in the Singleplex Immunoassay Market?** A: Pharmaceutical companies accounted for a market contribution of 60.0 to 90.0 USD Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/singleplex-immunoassay-market-6196*